Flemington, NJ
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)The National Immunotherapy Cancer, founded in 1990, is a small nonprofit in the Medical Research sector that reported $151K in total revenue in fiscal year 2023. Revenue surged 3324% from the prior year, signaling strong growth momentum. The organization ran a surplus of $53K, a strong 35% operating margin.
TO PROVIDE GRANTS TO SECTION 501(C)(3) ORGANIZATIONS THAT ADVANCE AND IMPROVE SCIENTIFIC RESEARCH IN IMMUNOTHERAPY AND TO ORGANIZATIONS THAT PROMOTE, ADVANCE AND IMPROVE EDUCATION AND SUPPORT CANCER PATIENTS
ALL OTHER ACCOMPLISHMENTS TO PROVIDE FUNDS FOR SERVICES TO PROGRAMS THAT SUPPORT INDIVIDUALS WITH CANCER, SUPPORTING SERVICES FOR INDIVIDUALS WITH CANCER, AND RESEARCH FOR CANCER
TO PROVIDE GRANTS TO FUND CAMPS AND OTHER SERVICES FOR CHILDREN WITH CANCER. THE HOLE IN THE WALL GANG - JULY 2020, A $1,000,000 GRANT COMMITMENT WAS MADE. THE GRANT WAS RECORDED ON THE 2020 RETURN...
TO PROVIDE GRANTS TO FUND CAMPS AND OTHER SERVICES FOR CHILDREN WITH CANCER. THE HOLE IN THE WALL GANG - JULY 2020, A $1,000,000 GRANT COMMITMENT WAS MADE. THE GRANT WAS RECORDED ON THE 2020 RETURN. THE GRANT IS BEING PAID OVER AN 8 YEAR PERIOD (YEARS 2020 THROUGH 2027) OF $125,000 PAID ANNUALLY
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2023 | 2022 | Change | |
|---|---|---|---|
| Revenue | $151,460 | $4,423 | +33.2% |
| Expenses | $98,040 | $136,357 | -0.3% |
| Net Income | $53,420 | $-131,934 | -1.4% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| DON GRIFFIN | Director | 1.00 |
Director
|
$0 | $0 | $0 |
| LAURA JOHNSON | Director | 1.00 |
Director
|
$0 | $0 | $0 |
| ROBERT A FACCHINA | President | 1.00 |
Officer
|
$0 | $0 | $0 |
| JEFFREY A WEST | Treasurer | 1.00 |
Officer
|
$0 | $0 | $0 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2024 | No data | No data | No data | No data |
| 2023 | $151,460 | $98,040 | $1,051,896 | $53,420 |
| 2022 | $4,423 | $136,357 | $1,104,751 | $-131,934 |
| 2021 | $6,004 | $77,669 | $1,361,131 | $-71,665 |
| 2020 | $13,978 | $1,023,158 | $1,557,796 | $-1,009,180 |
| 2019 | $330,414 | $32,577 | $1,728,276 | $297,837 |
| 2018 | $328,141 | $29,367 | $1,566,353 | $298,774 |
Compare The National Immunotherapy Cancer with other nonprofits in New Jersey and across the country.